Julian Baker’s Rein Therapeutics RNTX Stock Holding History

Julian Baker’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-102,000	Closed	-$1.47M	–	110
2019 Q2	$1.47M	Buy	+102,000	New	+$2.68M	0.01%	90

Other funds holding RNTX

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Julian Baker's RNTX Position: Q3 2019 in Review

Julian Baker sold out of Rein Therapeutics (RNTX) in Q3 2019, closing a stake of 102,000 shares — an estimated $1.47M sold.

Julian Baker first reported a position in RNTX in Q2 2019 and held it in 1 quarter. The position peaked at $1.47M in Q2 2019. 22 funds tracked by Wall St. Rank hold RNTX as of Q3 2019.

Julian Baker reported no remaining Rein Therapeutics position as of Q3 2019 after selling out during the quarter.
Julian Baker sold 102,000 Rein Therapeutics shares in Q3 2019, an estimated $1.47M.
Julian Baker first reported a position in Rein Therapeutics in Q2 2019 and held it in 1 quarter.
Julian Baker's Rein Therapeutics position peaked at $1.47M in Q2 2019.
22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2019.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.